Association Review
In brief
The association between FGFR2 (Fibroblast Growth Factor Receptor 2) and Esophageal Cancer is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
17
Compounds
1
Trials
59of 1,321 via FGFR2 compounds
Publications
0
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
3 source summaries
A gene summary alongside the source descriptions it was distilled from.
04
Esophageal Cancer
The disorder
40 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
05
Phenotype
Clinical features
1 clinical feature
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
06
Population genetics
GWAS signals
2 GWAS phenotypes
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
07
Interventions
Therapeutics
1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
08
Human studies
Clinical trials
1,321 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
09
Provenance
References & sources
10 references
Every source and publication cited across this dossier, as one numbered reference list.
